Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA)
Phase I/Ib Study With the Combination of RMC-4630 (SHP2 Inhibitor) and LY3214996 (ERK Inhibitor) in Metastatic KRAS Mutant CRC, PDAC and NSCLC
Sponsor: Lustgarten Foundation
Terminated
Due to a lack of safety and efficacy.
A PHASE1 clinical study on Colorectal Cancer and KRAS Mutation-Related Tumors, this trial is terminated or withdrawn. The trial is conducted by Lustgarten Foundation and has accumulated 8 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Feb 2025 — Present [monthly]
Terminated PHASE1
Status: Unknown → Terminated
-
Sep 2024 — Feb 2025 [monthly]
Unknown PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Jul 2022 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 3 earlier versions
-
Apr 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2021 — Mar 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Lustgarten Foundation
- The Netherlands Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .